AstraZeneca to Acquire Amolyt Pharma

AstraZeneca to Acquire Amolyt Pharma for Rare Endocrine Disease Portfolio

Rare Daily Staff

AstraZeneca will acquire Amolyt Pharma, expanding AstraZeneca Rare Diseases pipeline of therapeutic peptides targeting rare endocrine diseases.

Under the terms of the agreement, AstraZeneca will acquire all of Amolyt Pharma’s outstanding shares for a total consideration of up to $1.05 billion, on a cash and debt free basis. This includes $800 million upfront at deal closing, plus the right for Amolyt Pharma’s shareholders to receive an additional contingent payment of $250 million payable upon achievement of a specified regulatory milestone.

Amolyt’s clinical pipeline includes differentiated therapeutic peptides for the treatment of underserved rare endocrine disease. Eneboparatide (AZP-3601) is an investigational daily subcutaneous injectable parathyroid hormone receptor 1 (PTHR1) agonist for the treatment of hypoparathyroidism, that is currently in phase 3 clinical trials. AZP-3813 is a peptide growth hormone receptor antagonist for the potential treatment of acromegaly that is in phase 1 development.

“Chronic hypoparathyroid patients face a significant need for an alternative to current supportive therapies, which do not address the underlying hormone deficiency,” said Marc Dunoyer, CEO, Alexion, AstraZeneca Rare Disease. “Alexion is uniquely positioned to drive the late-stage development and global commercialization of eneboparatide, which has the potential to lessen the often debilitating impact of low parathyroid hormone and avoid the risks of high-dose calcium supplementation. We believe this program, together with Amolyt’s talented team, expertise, and earlier pipeline, will enable our expansion into rare

Subject to the satisfaction of customary closing conditions in the acquisition agreement, including regulatory clearances, the transaction is expected to close by the end of the third quarter of 2024.

Photo: Marc Dunoyer, CEO, Alexion, AstraZeneca Rare Disease